Insider
Alcon IncALC

Alcon presented data on SYSTANE PRO PF at Academy 2026

Alcon announced its participation in Academy 2026 in Anaheim (Sep 30 – Oct 3) and on Oct 1 presented study results showing SYSTANE PRO PF was non‑inferior to MIEBO in relieving dry‑eye symptoms.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
white and red exit sign
Photo by Cory Mogk on Unsplash

Key points

  • Alcon said it will take part in Academy 2026 in Anaheim and on Oct 1 released study results in which SYSTANE PRO PF was non‑inferior to MIEBO in easing dry‑eye symptoms.
  • The study involves patients with dry eye who can use SYSTANE PRO PF.
  • In a prospective, randomized study, SYSTANE PRO PF showed non‑inferiority to MIEBO in relieving dry eye, achieving the primary endpoint of non‑inferiority on the OSDI scale at two weeks and one month.

What happened

Alcon said it will take part in Academy 2026 in Anaheim and on Oct 1 released study results in which SYSTANE PRO PF was non‑inferior to MIEBO in easing dry‑eye symptoms.

Who is affected

The study involves patients with dry eye who can use SYSTANE PRO PF.

Evidence

In a prospective, randomized study, SYSTANE PRO PF showed non‑inferiority to MIEBO in relieving dry eye, achieving the primary endpoint of non‑inferiority on the OSDI scale at two weeks and one month.

Next steps

Alcon gave no details on further regulatory or commercial actions; assessing the results’ impact will require additional data on physician uptake and formulary inclusion.

Original sources

  1. Alcon to Showcase Extensive Scientific Research, Immersive Experiences and Innovation at Academy 2026September 28, 2026SHA-256 of our archived copy b4b9bf7a7280…
  2. SYSTANE PRO Preservative-Free Demonstrates Clinically Comparable Dry Eye Symptom Relief to MIEBO (perfluorohexyloctane ophthalmic solution) in a Prospective, Randomized Clinical StudyOctober 1, 2026SHA-256 of our archived copy 4b5f9a69cc7b…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards